Intelligence Feed event · Policy · 2026-09-03

    Nxera Pharma Receives $8.6M Milestone From Eli Lilly Subsidiary Centessa on OX2R Agonist

    Question

    Nxera Pharma Receives $8.6M Milestone From Eli Lilly Subsidiary Centessa on OX2R Agonist

    Direct answer

    Nxera Pharma announced receipt of an $8.6 million milestone payment from Centessa Pharmaceuticals, an Eli Lilly subsidiary, following late-stage development advancements for selective orexin receptor 2 (OX2R) agonist candidates. The milestone will be booked as Q3 2026 revenue. The progress underscores ongoing pharmaceutical interest and clinical advancement in next-generation sleep disorder and neurological indications targeting the orexin pathway.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Nxera Pharma Receives $8.6M Milestone From Eli Lilly Subsidiary Centessa on OX2R Agonist”, revision 1, evidence through 2026-09-03. https://marketontology.com/market-events/2026-09-03/nxera-pharma-receives-8-6m-milestone-from-eli-lilly-subsidiary-centessa-on-ox2r-a6c2eb

    POLICY
    Nxera Pharma Receives $8.6M Milestone From Eli Lilly Subsidiary Centessa on OX2R Agonist
    Nxera Pharma announced receipt of an $8.6 million milestone payment from Centessa Pharmaceuticals, an Eli Lilly subsidiary, following late-stage development advancements for selective orexin receptor 2 (OX2R) agonist candidates. The milestone will be booked as Q3 2026 revenue. The progress underscores ongoing pharmaceutical interest and clinical advancement in next-generation sleep disorder and neurological indications targeting the orexin pathway.
    LLY
    Impact
    68
    SEP 3
    SIG
    90%
    LLY
    Nxera Pharma Receives $8.6M Milestone From Eli Lilly Subsidiary Centessa on OX2R Agonist
    Nxera Pharma announced receipt of an $8.6 million milestone payment from Centessa Pharmaceuticals, an Eli Lilly subsidiary, following late-stage development advancements for selective orexin receptor 2 (OX2R) agonist candidates. The milestone will be booked as Q3 2026 revenue. The progress underscores ongoing pharmaceutical interest and clinical advancement in next-generation sleep disorder and neurological indications targeting the orexin pathway.
    → Advancement of selective OX2R agonists into late-stage trials expands LLY neuroscience pipeline commercialization potential and validates Nxera royalty streams.
    Impact
    Nxera Pharma announced receipt of an $8.6 million milestone payment from Centessa Pharmaceuticals, an Eli Lilly subsidiary, following late-stage development advancements for selective orexin receptor 2 (OX2R) agonist candidates. The milestone will be booked as Q3 2026 revenue. The progress underscores ongoing pharmaceutical interest and clinical advancement in next-generation sleep disorder and neurological indications targeting the orexin pathway.
    Affected
    LLY
    Transmission
    Advancement of selective OX2R agonists into late-stage trials expands LLY neuroscience pipeline commercialization potential and validates Nxera royalty streams.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYpipeline expansion in selective orexin receptor neurological therapiesUp1-3mSubsidiary Centessa achieved late-stage development milestone on OX2R agonist.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month